This compound is primarily investigated for its potential therapeutic applications in treating gastrointestinal disorders, particularly irritable bowel syndrome with constipation (IBS-C). It acts as a selective inhibitor of the RET receptor tyrosine kinase, which plays a role in regulating gut motility and secretion. By targeting this pathway, it aims to alleviate symptoms such as abdominal pain, bloating, and constipation, offering a novel approach to managing IBS-C. Research continues to explore its efficacy and safety in clinical trials, with the goal of providing a targeted treatment option for patients with limited response to existing therapies.